Alnylam Pharmaceuticals
E100609
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Alnylam Pharmaceuticals canonical | 1 |
| Alnylam Pharmaceuticals Ireland | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T839865 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alnylam Pharmaceuticals Context triple: [Phillip A. Sharp, coFounded, Alnylam Pharmaceuticals]
-
A.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Gilead Sciences (board member)
Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate known for its portfolio of life sciences, diagnostics, and industrial solutions businesses.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Alnylam Pharmaceuticals Target entity description: Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
A.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Gilead Sciences (board member)
Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate known for its portfolio of life sciences, diagnostics, and industrial solutions businesses.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| collaboratesWith |
Novartis
ⓘ
Regeneron Pharmaceuticals ⓘ Roche ⓘ Sanofi ⓘ Vir Biotechnology ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
Amvuttra
ⓘ
Givlaari ⓘ Onpattro ⓘ Oxlumo ⓘ |
| focusesOn |
cardiometabolic diseases
ⓘ
central nervous system diseases ⓘ hepatic infectious diseases ⓘ rare genetic diseases ⓘ |
| foundedBy |
David Bartel
ⓘ
John Maraganore ⓘ Paul Schimmel ⓘ Phil Zamore ⓘ Phillip A. Sharp ⓘ Thomas Tuschl ⓘ |
| hasClinicalStagePrograms |
ATTR amyloidosis
ⓘ
cardiovascular disease ⓘ hemophilia ⓘ hypercholesterolemia ⓘ hypertension ⓘ |
| hasIndication |
acute hepatic porphyria
ⓘ
hereditary transthyretin-mediated amyloidosis ⓘ polyneuropathy of hereditary transthyretin-mediated amyloidosis ⓘ primary hyperoxaluria type 1 ⓘ |
| hasSubsidiary |
Alnylam Pharmaceuticals
self-linksurface differs
ⓘ
surface form:
Alnylam Pharmaceuticals Ireland
|
| headquartersLocation |
Cambridge, Massachusetts
ⓘ
surface form:
Cambridge, Massachusetts, United States
|
| inception | 2002 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn | NASDAQ ⓘ |
| missionStatement | to transform the lives of patients with RNAi therapeutics ⓘ |
| productType | RNAi therapeutic ⓘ |
| researchArea |
gene silencing
ⓘ
siRNA therapeutics ⓘ |
| specializesIn |
RNA interference therapeutics
ⓘ
RNAi-based drugs for genetically defined diseases ⓘ |
| targetOrgan | liver ⓘ |
| technologyPlatform | RNA interference ⓘ |
| tickerSymbol | ALNY ⓘ |
| usesDeliveryTechnology | GalNAc conjugate delivery ⓘ |
| website | https://www.alnylam.com ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Alnylam Pharmaceuticals Description of subject: Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Alnylam Pharmaceuticals Ireland